The Role of Interferon in the Treatment of Chronic Myelogenous Leukemia: Results and Prospects

References

• Failkow P. J., Jakobson R. J., Papayannopoulou T. Clonal origin in a stem cell common to the granulocyte. erythrocyte, platelet and monocyte macrophage. American Journal of Medicine 1977; 6: 125–130
   Web of Science ®Google Scholar
• Rowley J. D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290–293
   PubMed Web of Science ®Google Scholar
• Shtivelman E., Lifshitz B., Gale R. P., Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 1985; 315: 550–554
   PubMed Web of Science ®Google Scholar
• Kloetzer W., Kurzrock R., Smith L., Talpaz M., Spiller M., Gutterman J., Arlinghaus R. The human cellular abl gene product in the chronic myelogenous leukemia cell line K 562 has an associated tyrosine protein kinase activity. Virology 1985; 140: 230–238
   PubMed Web of Science ®Google Scholar
• Champlin R. E., Golde D. W. Chronic myelogenous leukemia: recent advances. Blood 1985; 65: 1039–1047
   PubMed Web of Science ®Google Scholar
• Lazzarino M., Morra E., Brusamolino E., Inverardi D., Castelli G., Merantc S., Bernasconi C. Hydroxyurea and 6-mcrcaptopurine in the treatment of chronic granulocytic leukemia. American Journal of Clinical Oncology (CCT) 1986; 9: 45–49
   PubMed Web of Science ®Google Scholar
• Cunningham I., Gee T., Dowling M., Chaganti R., Bailey R., Hopfan S., Bowden L., Turnbull A., Knapper W., Clarkson B. Results of treatment of Ph1 chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol). Blood 1979; 53: 375–395
   PubMed Web of Science ®Google Scholar
• Baccarani M., Corbelli G., Tura S. Early splenectomy and polychemotherapy versus polychemotherapy alone in chronic myeloid leukemia. Leukemia Research 1981; 5: 149–157
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Vellekoop L., McCredie K. B., Keating M. J., Hester J., Smith T., Barlogie B., Trujillo J., Freircieh E. J. Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic granulocytic leukemia. Journal of Clinical Oncology 1985; 3: 192–200
   PubMed Web of Science ®Google Scholar
• Goldman J. M., Perley J. F., Jones L., Marcus R., Goolden A. W. G., Batchelor R., Hale G., Waldmann H., Reid C. D., Hows J., Gordon-Smith E., Catovsky D., Galton D. A. G. Bone marrow transplantation for patients with chronic myeloid leukemia. New England Journal of Medicine 1986; 314: 202–220
   PubMed Web of Science ®Google Scholar
• Verma D. S., Spitzer G., Guttermann J. U., Zander A. R., McCredie K. B., Dicke K. A. Human leukocyte interferon blocks granulopoietic differentiation. Blood 1979; 54: 1423–1427
   PubMed Web of Science ®Google Scholar
• Oladipupo-Williams C. K., Svet-Moldavskaya I., Vilcek J., Ohnuma T., Holland J. D. Inhibitory effect of human leukocyte and fibroblast interferons on normal and chronic myelogenous leukemia granulocytic progenitor cells. Oncology 1981; 38: 356–360
   PubMed Web of Science ®Google Scholar
• Gutterman J. U., Blumenschein G. R., Alexanian R. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Annals of Internal Medicine 1980; 93: 399–406
   PubMed Web of Science ®Google Scholar
• Quesada J. R., Swanson D. A., Trindade A., Gutterman J. U. Renal cell carcinoma: Antitumor effects of leucocyte interferon. Cancer Research 1983; 43: 940–943
   PubMed Web of Science ®Google Scholar
• Talpaz M., McCredie B., Mavligit G. M., Gutterman J. U. Leukocyte interferon induced myeloid cytoreduc-tion in chronic myelogenous leukemia. Blood 1983; 62: 689–692
   PubMed Web of Science ®Google Scholar
• Talpaz M., Mavligit G. M., Keating M. J., Walters R. S., Gutterman J. U. Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Annals of Internal Medicine 1983; 99: 789–792
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian J., McCredie K., Keating M. J., Trujillo J., Gutterman J. U. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987; 69: 1280–1288
   PubMed Web of Science ®Google Scholar
• Talpaz M., McCredie K., Kantarjian H., Trujillo J., Keating M., Gutterman J. U. Chronic myelogenous leukemia: hematologic remissions with alpha interferon. British Journal of Haematology 1986; 64: 87–95
   PubMed Web of Science ®Google Scholar
• Talpaz M. Therapy of chronic myelogenous leukemia. Chemotherapy and Interferons. Seminars in Oncologv 1988; 25: 62–73
   Google Scholar
• Talpaz M., Kantarjian H., Kurzrock R., Trujillo J. M., Gutterman J. U. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome-positive patients. Annals of Internal Medicine 1991; 114: 532–538
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H., McCredie K., Trujillio J. M., Keating M. J., Gutterman J. U. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alphaA in chronic myelogenous leukemia. New England Journal of Medicine 1986; 314: 1065–1069
   PubMed Web of Science ®Google Scholar
• Niederle N., Kloke O., May D., Becher R., Osieka R., Schmidt C. G. Treatment of chronic myelogenous leukemia with recombinant interferon alfa-2b. Investigational New Drugs 1987; 5(suppl)19–25
   Google Scholar
• Alimena G., Morra E., Lazzarino M., Liberati A. M., Montefusco E., Inverardi D., Bernasconi P., Mancini M., Donti E., Grignani F., Bernasconi C., Dianzani F., Mandelli F. Interferon alpha-2b as therapy for Ph11-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 1988; 72: 642–647
   PubMed Web of Science ®Google Scholar
• Ozer H., Dear K., Testa J., Arthur D., Cooper R., Pettenati M., Rao K., Peterson B. A., Schifler C., Bloomfield C. D. CALG-B Prolonged administration of subcutaneous α-Interferon induces major clinical and complete cytogenetic remissions in untreated Philadelphia positive (Ph1+) chronic myelogenous leukemia. Proceeding of the American Society of Clinical Oncology 1990; 203a
   Google Scholar
• Freund M., von Wussow P., Diedrich H., Eisert R., Link H., Wilk H., Buchholz F., Leblanc S., Fonatsch C., Deicher R. H., Poliwoda H. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing antibodies. British Journal of Haematology 1989; 72: 350–356
   PubMed Web of Science ®Google Scholar
• Gastl G., Aulitzky W., Tilg G., Luttichau I., Machimayr G., Gadner H., Coser C., Seewann H. L., Huber H., Huber C. H. Recombinant IFN α-2 for treatment of chronic myelogenous leukemia in benign and accelerated phase. Journal of Interferon Research 1987; 7: 737
   Google Scholar
• Russo D., Fanin R., Zuffa E., Gallizia C., Michieli M. G., Damiani D., Testoni N., Pecile V., Visani G., Colombini R., Tosi P., Baccarani M., Tura S. Treatment of Ph1+ chronic myeloid leukemia by gamma Interferon. Blut 1989; 59: 15–20
   PubMedGoogle Scholar
• Kurzrock R., Talpaz M., Kantarjian H., Walters R., Saks S., Trujillo J. M., Gutterman J. U. Therapy of chronic myelogenous leukemia with recombinant interferon gamma. Blood 1987; 70: 943–947
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kurzrock R., Kantarjian H., et al. Therapy of Philadelphia positive chronic myelogenous leukemia (CML Ph1) with recombinant alpha 2A interferon and recombinant gamma interferon. Blood 1988; 72: 229a
   Google Scholar
• Niederle N. Interferon in patients with chronic myelogenous leukemia. Proceedings on the First International Symposium on Cytokines in Hemopoiesis, Oncology, and AIDS (Hannover, June 1989). Molecular Biotherapy 1989; 1: 75a
   Google Scholar
• Kantarjian H., Keating M., Mc Credie K., Gutterman J., Freireich E., Deisseroth A., Talpaz M. Treatment of advanced stages of Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) with alpha interferon (IFN-A) and low dose cytosine arabinoside (Ara-C). Blood 1989; 74(suppl 1)235a.
   Google Scholar
• Talpaz M., Kantarjian H., Kurzrock R., Gutterman J. U. Update on therapeutic options for chronic myelogenous leukemia. Seminars in Hematology 1990; 27(suppl.4)31–36
   PubMedGoogle Scholar
• Yoffe G., Blick M., Kantarjian H., Spitzer G., Gutterman J., Talpaz M. Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia. Blood 1987; 69: 961–963
   PubMed Web of Science ®Google Scholar
• Morra E., Alimena G., Lazzarino M., Liberati A. M., Montefusco E., Inverardi D., Bernasconi P., Mancini M., Donti E., Grignani F., Bernasconi C., Dianzani F., Mandelli F. Treatment of Ph1 positive chronic myelogenous leukemia with interferon alpha-2b. New Trends in the Therapy of Leukemia and Lymphoma 1987; 2: 75–82
   Google Scholar
• Alimena G., Morra E., Lazzarino M., Liberati A. M., Montefusco E., Inverardi D., Bernasconi P., Mancini M., Donti E., Grignani F., Bernasconi C., Dianzani F., Mandelli F. Interferon alpha-2b as therapy for patients with Ph1 positive chronic myelogenous leukemia. European Journal of Hematology 1990; 45(suppl 52)25–28
   Google Scholar
• Morra E., Alimena G., Lazzarino M., Liberati A. M., Montefusco E., Inverardi D., Bernasconi P., Mancini M., Donti E., Grignani F., Bernasconi C., Dianzani F., Mandelli F. Interferon as therapy for untreated and pretreated patients with Ph1+ chronic myelogenous leukemia. Cytokines in Hemopoiesis, Oncology, and AIDS, M. Freund, H. Link, K. Welte. Springer Verlag, Berlin 1990; 503–11
   Google Scholar
• Sokal J. E., Baccarani M., Tura S., Gomez G. A., Robertson J. E., Tsao C. Y., Braun T. J., Clarkson B. D., Cervantes F., Rozman C., Italian Cooperative C ML. Study Group Prognostic discrimination in good-risk chronic granulocytic leukemia. Blood 1984; 63: 789–99
   PubMed Web of Science ®Google Scholar
• Tura S., Russo D., Zuffa E., Fiacchini M. for the Italian Cooperative Study Group on CMLA prospective comparison of human recombinant interferon α-2a (Roferon-A) and conventional chemotherapy in Chronic Myeloid Leukemia. Interim report on the Italian study. Blood 1990; 76(suppl 1)329a
   Google Scholar
• Hehlmann R., Anger B., Messerer D., et al. Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha. Blut 1988; 56: 87–91
   PubMedGoogle Scholar
• Hehlmann R., Heimpel H., Heinze B., Hasford J., Kolb H. J., Georgii A. B., German C ML. Study Group Prospective controlled comparison of busulfan versus hydroxyurea versus interferon alpha in chronic myelogenous leukemia (CML). Blood 1990; 76(suppl. 1)279a
   PubMedGoogle Scholar
• Geissler D., Gastl G., Aulitzky W., Tilg H., Gaggl S., Konwalinka G., Huber C. Recombinant interferon-alpha-2c in chronic myelogenous leukaemia: relationship of sensitivity of committed haematopoietic precursor cells in vitro (BFU-E, CFU-GM, CFU-Meg) and clinical response. Leukemia Research 1990; 14: 629–636
   PubMed Web of Science ®Google Scholar
• McClave P., Mamus S., Vilen B., Dewald G. Effect of recombinant gamma interferon on chronic myelogenous leukemia bone marrow progenitors. Experimental Haematology 1984; 15: 331–338
   Google Scholar
• Herrmann F., Jonas D., Helfrich S. G., Lindemann A., Schleiermacher E., Mertelsmann R. Interferon alfa-2C in chronic myelogenous leukemia (CML): hematologic, cytogenetic and molecular-genetic response of patients with chronic phase CML previously resistant to therapy with interferon gamma. Blut 1990; 61: 226–231
   PubMedGoogle Scholar
• Silver R. T., Reich S. D., Coleman P., et al. Gamma interferon (IFN) has activity in treating chronic myeloid leukemia (CML). Blood 1986; 68(suppl 1)232a
   Google Scholar
• Maxwell L. N., Talpaz M., Gutterman J. Down-regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon therapy. International Journal of Cancer 1985; 36: 23–8
   PubMed Web of Science ®Google Scholar
• Tura S., Baccarani M., Corbelli G. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Staging of chronic myelogenous leukemia. British Journal of Haematology 1981; 47: 105–119
   PubMed Web of Science ®Google Scholar
• Sokal J. E., Baccarani M., Russo D., Tura S. Staging and prognosis in chronic myelogenous leukemia. Seminars in Hematology 1988; 25: 49–61
   PubMed Web of Science ®Google Scholar
• Dhingra K., Kurzrock R., Kantarjian H., Gutterman J. U., Talpaz M. Polymerase chain reaction (PCR) for minimal residual disease in 20 CML in complete cytogenetic response induced by interferon therapy. Blood 1989; 74(suppl 1)235a
   Google Scholar
• Geissler G., Gastl G., Konwalinka G. Antileukemic effect of r IFN-alpha in CML: comparison in vitro and in vivo. Blut 1986; 53: 239–240
   Google Scholar
• Carlo-Stella C., Cazzola M. Interferons as biological modulators of hematopoietic cell proliferation and differentiation. Haematologica 1988; 73: 225–237
   PubMedGoogle Scholar
• Dowding C., Guo A. P., Maisin D., Gordon M. Y., Goldman J. M. The effects of interferon-α on the proliferation of CML progenitor cells in vitro are not related to the precise position of the M-BCR breakpoint. British Journal of Haematology 1991; 77: 165–171
   PubMed Web of Science ®Google Scholar
• Kantarjian H., Talpaz M., Gutterman H. Biologic therapy of chronic myelogenous leukemia. Oncology. 1987; 1: 35–40
   PubMedGoogle Scholar
• Friedman R. Growth factors and Oncogenes. Modulation of growth and differentiation by Interferons. Interferons in cancer treatment, H. K. B. Silver. Medical Education Services, Ontario Canada 1986; 11–16
   Google Scholar
• Galvani D. W., Cawley J. C. Mechanism of action of α-interferon in chronic granulocytic leukemia: evidence of preferential inhibition of late progenitors. British Journal of Haematology 1989; 73: 475–479
   PubMed Web of Science ®Google Scholar
• Galvani D. W., Cawley J. C. The effects of α interferon on human long-term bone marrow culture. Leukemia Research 1990; 14: 525–531
   PubMed Web of Science ®Google Scholar
• Schiller J. H., Groveman D. S., Schmid S. W., Willson J. K. W., Cummings K. B., Boerden E. C. Synergistic antiproliferative effects of human recombinant alpha 54 or beta interferon with gamma-interferon on human cell lines of various histogenesis. Cancer Research 1986; 46: 483
   PubMed Web of Science ®Google Scholar
• Kloke O., Wandl U., Opalka B., May D., Becher R., Nagel-Hiemke M., Schmidt C. G., Niederle N. A randomized trial of Interferon (IFN) alfa or IFN alfa plus IFN gamma for the treatment of Philadelphia chromosome (PH) positive chronic myelogenous leukemia (CML): preliminary results. Blood 1989; 74((suppl 1))277a
   Google Scholar
• Ozer H. Biotherapy of chronic myelogenous leukemia with interferon. Seminars in Oncology 1988; 15: 14–20
   PubMed Web of Science ®Google Scholar
• Bergsagel D. R., Haas R. H., Messner H. A. Interferon α-2b in the treatment of chronic granulocytic leukemia. Seminars in Oncology 1986; 13: 29–34
   PubMed Web of Science ®Google Scholar
• Aapro M. S., Alberts D. S., Salmon S. E. Interaction of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemotherapy Pharmacology 1983; 10: 161–166
   PubMed Web of Science ®Google Scholar
• Welander C. E., Morgan T. M., Homesley M. D., Trotta P. P., Spiegel R. J. Combined recombinant interferon alpha-2 and cytotoxic agents studied in clonogenic assay. International Journal of Cancer 1985; 35: 721–729
   PubMed Web of Science ®Google Scholar
• Bernasconi C., Morra E. The combination of alpha interferon with other antineoplastic agents. New Trends in the Therapy of Leukemia and Lymphoma 1987; 2: 31–35
   Google Scholar
• Shtalrid M., Lugassy G., Berrebi A. High response rate to recombinant interferon alpha in chronic myeloid leukemia after intensive cytoreductive chemotherapy. Blood 1989; 74(suppl 1)370a
   Google Scholar
• Guilhot F., Dreyfus B., Brizard A., Huret J. L., Tanzer J. Cytogenetic remissions in chronic myelogenous leukemia using Interferon Alpha-2a and hydroxyurea with or without low-dose cytosine arabinoside. Leukemia and Lymphoma 1991; 4: 49–55
   PubMed Web of Science ®Google Scholar
• Kantarjian H., Talpaz M., Keating M., Walters R. S., McCredie K. B., Freireich E. J., Gutterman J. U. Therapy of Philadelphia chromosome positive chronic myelogenous leukemia (CML) with initial intensive chemotherapy (DOAP) followed by maintenance with human leukocyte alpha interferon. Blood 1986; 68: 224
   Google Scholar
• Kantarjian H. M., Talpaz M. Treatment of chronic myelogenous leukemia with interferons. Proceedings of the Fifth European Conference on Clinical Oncology, Satellite Symposium on Intron A (Interferon Alfa-2b) and GM-CSF in Clinical Oncology: Status and prospects, London, 1989
   Google Scholar
• Burke P. J., Rowley S. D. Remission of aggressive phase chronic myelocytic leukemia (CML) with timed sequential therapy (TST) and interferon (I) given in aplasia. Blood 1990; 76(suppl 1)258a
   Google Scholar
• Meloni G., De Fabritiis P., Alimena G., Malagnino F., Montefusco E., Sandrelli A., Pinto R., Vignetti M., Lo Coco F., Mandelli F. Autologous bone marrow or peripheral blood stem cell transplantation for patients with chronic myelogenous leukemia in chronic phase. Bone Marrow Transplantation 1989; 4(suppl 4)92–94
   PubMedGoogle Scholar
• McGlave P. B., Arthur D., Miller W. J., Lasky L., Kersey J. Autologous transplantation for CML using marrow treated ex vivo with recombinant human interferon gamma. Bone Marrow Transplantation 1990; 6: 115–120
   PubMed Web of Science ®Google Scholar
• Reiffers J., Trouette R., Marit G., et al. Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: a report of 47 cases. British Journal of Haematology 1991; 77: 339–345
   PubMed Web of Science ®Google Scholar
• Newland A. C., Jones L., Mir N., Slocombe G. W. Alpha 2 interferon in chronic myelogenous leukemia following relapse post-allogeneic transplant. British Journal of Haematology 1987; 66: 141–143
   PubMed Web of Science ®Google Scholar
• Arcese W., Mauro F., Alimena G., Lo Coco F., De Cuia M. R., Screnci M., Iori A. P., Montefusco E., Mandelli F. Interferon therapy for Ph1 positive CML patients relapsing after T-cell depleted allogeneic BMT. Bone Marrow Transplantation 1990; 5: 309–315
   PubMed Web of Science ®Google Scholar
• Higano C. S., Raskind W., Durnam D., Singer J. W. Alpha interferon induces cytogenetic remissions in patients who relapse with chronic myelogenous leukemia (CML) after allogeneic bone marrow transplantation. Journal of Cellular Biochemistry 1989; 116a
   Google Scholar
• Balkwill F. R. Antitumor effects of interferons in animals. Interferon vol. 4. In vivo and clinical studies, N. B. Finter, R. K. Oldham. Elsevier, Amsterdam 1985; 23–45
   Google Scholar
• Bonnem E. Alfa Interferon: Combinations with other antineoplastic modalities. Seminars in Oncology 1987; 14(suppl 2)48–60
   PubMed Web of Science ®Google Scholar
• Sokal J. E., Gockerman J. P., Bigner S. H. Evidence for a selective anti leukemic effect of cytosine arabinoside in chronic granulocytic leukemia. Leukemia Research 1988; 12: 453–458
   PubMed Web of Science ®Google Scholar
• Cannistra S., Tantravahi R., Robertson M. J., Griffin J., Canellos G. P. Low-dose cytosine arabinoside (Ara-C) induces cytogenetic remissions in patients with stable-phase chronic myeloid leukemia (CML). Blood 1990; 76(suppl 1)259a
   Google Scholar